Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01488890

Enrollment

390

Registered

2011-12-08

Start date

2011-12-06

Completion date

2013-09-27

Last updated

2022-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever

Keywords

Dengue fever, Dengue Hemorrhagic Fever, CYD dengue vaccine, Yellow Fever, Flavivirus

Brief summary

The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations. Primary Objectives: * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue vaccine Dose 3 in Group 1 (Month \[M\] 13) and Group 2 (M07), irrespective of whether or not Yellow Fever (YF) vaccine has been previously administered. * To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes 6 months after CYD dengue vaccine Dose 3 in Group 1 (M18) and Group 2 (M12), irrespective of whether or not YF vaccine has been previously administered. Secondary Objective: * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue vaccine Dose 1 and Dose 2 in Groups 1 and 2, irrespective of whether or not YF vaccine has been previously administered. * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue Dose 1 in the combined YF-participants in Group 1 (N=60) and Group 2 (N=60), and in Group 3 (N=120). * To describe by FV status at baseline the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each injection of CYD dengue vaccine in Groups 1, 2, and 3. * To describe the safety profile after each injection of CYD dengue vaccine and/or YF vaccine.

Detailed description

Participants were randomized to 4 different groups to receive either CYD dengue vaccine and/or YF vaccine. Participants who already received YF vaccine prior to enrolment were randomized to one of the 2 groups receiving CYD dengue vaccine alone. Participants were evaluated for immunogenicity, antibody persistence, reactogenicity and safety.

Interventions

BIOLOGICALLive, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

0.5 mL, Subcutaneous

BIOLOGICALYellow Fever

0.5 mL, Subcutaneous

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Aged \>= 18 to \<= 45 years on the day of inclusion * Informed consent form had been signed and dated * Able to attend all scheduled visits and complied with all trial procedures * For participants classified as YF positive (+) to be included in Groups 1 and 2, previous vaccination (3 months to 10 years) with YF vaccine confirmed by acceptable documentation.

Exclusion criteria

* Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination) * Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks following each trial vaccination * For all participants classified as YF negative (-), any previous vaccination against Flavivirus (FV) diseases (including Japanese Encephalitis \[JE\], tick-borne encephalitis, and YF) * For participants classified as YF+, previous vaccination against FV diseases except YF (including JE and tick-borne encephalitis) * For all participants, any FV vaccination planned during the trial period outside the study protocol * Receipt of immune globulins, blood or blood-derived products in the past 3 months * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Self-reported seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Self-reported history of FV infection (e.g., JE, Dengue, YF, West Nile), confirmed either clinically or serologically * Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances, including dry natural latex * Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily * Current alcohol abuse or drug addiction * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion * Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator * Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \>= 38.0°C \[\>=100.4°F\]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided * Previous residence (\> 12 months) in, or travel in the last 30 days to FV endemic regions * History of thymic pathology (thymoma), thymectomy, or myasthenia.

Design outcomes

Primary

Measure	Time frame	Description
Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Pre-injection 1, 28 days and 6 months post-injection 3	GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue plaque reduction neutralization test (PRNT).
Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Pre-injection 1, 28 days and 6 months post-injection 3	Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution).

Secondary

Measure	Time frame	Description
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Pre-injection 1 and 28 days post-injection 1	GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue plaque reduction neutralization test-50 (PRNT50). Groups 1 and 2 data was reported as pooled data. YF-non immune participants were defined as participants with YF baseline titer PRNT80 \< 10 (1/dilution).
Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Pre-injection 1 and 28 days post-injection 1	Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). Groups 1 and 2 data was reported as pooled data. YF-non immune participants were defined as participants with YF baseline titer dengue plaque reduction neutralization test-80 (PRNT80) \<10 (1/dilution).
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Pre Injection 1, 2 and 3 and 28 days post injection 1, 2 and 3	GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT. FV immune participants were defined as participants with titer \>= 10 (1/dilution) for at least 1 serotype with parental dengue virus strain (sera tested by PRNT) or with titer \>= 10 (1/dilution) for YF virus (sera with PRNT80 result).
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Pre-injection 1, 2, 3 and 28 days post-injection 1, 2 and 3	GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT. FV non-immune participants were defined as participants with titer \< 10 (1/dilution) for all serotypes with parental dengue virus strains (sera tested by PRNT) and with titer \<10 (1/dilution) for YF virus (using sera with PRNT80 result).
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Pre-injection 1 and 2 and 28 days post-injection 1 and 2	GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT.
Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Pre injection 1, 2, 3 and 28 days post injection 1, 2 and 3	Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). FV non-immune participants were defined as participants with titer \< 10 (1/dilution) for all serotypes with parental dengue virus strains (sera tested by PRNT) and with titer \<10 (1/dilution) for YF virus (using sera with PRNT80 result).
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Within 7 days after any injection	Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: \>100 mm.
Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Within 14 days after any injection	Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: \>= 39.0°C; Headache, Malaise, Myalgia, and Asthenia: significant; prevents daily activity.
Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Pre-injection 1, 2, 3 and 28 days post-injection 1, 2 and 3	Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). FV immune participants at baseline were defined as participants with titer \>= 10 (1/dilution) for at least 1 serotype with parental dengue virus strain (sera tested by PRNT) or with titer \>=10 (1/dilution) for YF virus (sera with PRNT80 result).
Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Pre-injection 1 and 2 and 28 days post-injection 1 and 2	Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution).

Countries

United States

Participant flow

Recruitment details

Study participants were enrolled from 06 December 2011 to 22 March 2012 in the United States.

Pre-assignment details

A total of 390 participants were enrolled and randomized in the study.

Participants by arm

Arm	Count
CYD Dengue Vaccine: Group 1 Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.	120
CYD Dengue Vaccine: Group 2 Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.	120
CYD Dengue and Yellow Fever Vaccine: Group 3 Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.	120
Yellow Fever Vaccine: Group 4 Participants received single dose of YF vaccine at Day 0.	30
Total	390

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Lost to Follow-up	13	10	20	3
Overall Study	Protocol Violation	3	0	4	0
Overall Study	Serious adverse event	2	0	0	0
Overall Study	Withdrawal by Subject	14	10	11	2

Baseline characteristics

Characteristic	CYD Dengue Vaccine: Group 1	CYD Dengue Vaccine: Group 2	CYD Dengue and Yellow Fever Vaccine: Group 3	Yellow Fever Vaccine: Group 4	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	120 Participants	120 Participants	120 Participants	30 Participants	390 Participants
Age, Continuous	31.6 Years STANDARD_DEVIATION 7.63	32.6 Years STANDARD_DEVIATION 7.32	32.6 Years STANDARD_DEVIATION 7.52	34.8 Years STANDARD_DEVIATION 8.63	32.5 Years STANDARD_DEVIATION 7.59
Sex: Female, Male Female	57 Participants	61 Participants	60 Participants	17 Participants	195 Participants
Sex: Female, Male Male	63 Participants	59 Participants	60 Participants	13 Participants	195 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 120	0 / 120	0 / 119	0 / 30
other Total, other adverse events	91 / 120	92 / 120	92 / 119	17 / 30
serious Total, serious adverse events	4 / 120	4 / 120	5 / 119	0 / 30

Outcome results

Primary

Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2

GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue plaque reduction neutralization test (PRNT).

Time frame: Pre-injection 1, 28 days and 6 months post-injection 3

Population: Full Analysis Set included participants who received at least 1 Inj. of CYD dengue or/ YF vaccine, had at least 1 blood sample drawn and valid post-Inj. serology result. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected, analyzed for Group 3 and 4.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	5.38 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 3	14.8 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 6 months Post-injection 3	13.3 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	5.19 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 3	51.2 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 6 months Post-injection 3	45.6 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection	5.32 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 3	45.7 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 6 months Post-injection 3	30.2 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	5.78 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Post-injection 3	66.8 Titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 6 months Post-injection 3	74.8 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Post-injection 3	83.1 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	5.13 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection	5.28 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 3	15.9 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	5.11 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 6 months Post-injection 3	9.01 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 3	59.3 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	5.22 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 6 months Post-injection 3	41.7 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 3	59.9 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 6 months Post-injection 3	34.5 Titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 6 months Post-injection 3	38.7 Titers (1/dilution)

Primary

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2

Time frame: Pre-injection 1, 28 days and 6 months post-injection 3

Population: Analysis was performed on Full Analysis Set. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected, analyzed for Group 3 and 4.

Arm	Measure	Group	Value (NUMBER)
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	1.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 3	52.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 6 months Post-injection 3	47.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	0.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 3	84.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 6 months Post-injection 3	75.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	2.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 3	85.1 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 6 months Post-injection 3	79.5 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	6.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 3	88.3 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 6 months Post-injection 3	86.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 3	86.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	2.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	4.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 3	56.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	0.8 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 1: 6 months Post-injection 3	32.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 3	90.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	2.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 4: 6 months Post-injection 3	74.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 3	88.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 3: 6 months Post-injection 3	80.8 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2	Dengue Virus Serotype 2: 6 months Post-injection 3	80.8 percentage of participants

Secondary

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)

GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT. FV immune participants were defined as participants with titer \>= 10 (1/dilution) for at least 1 serotype with parental dengue virus strain (sera tested by PRNT) or with titer \>= 10 (1/dilution) for YF virus (sera with PRNT80 result).

Time frame: Pre Injection 1, 2 and 3 and 28 days post injection 1, 2 and 3

Population: Analysis was performed on Full Analysis Set. Here, Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure and 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	5.35 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	13.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	18.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	25.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	12.7 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	15.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	5.73 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	48.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	72.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	83.7 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	43.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	60.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	5.61 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	45.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	47.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	72.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	29.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	44.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	6.55 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	78.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	65.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	89.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	40.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	51.7 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	88.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	5.23 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	5.53 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	48.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	9.25 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	62.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	65.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	12.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	31.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	68.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	16.7 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	74.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	71.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	10.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	41.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	68.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	17.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	45.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	78.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	5.42 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	69.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	5.20 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	34.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	77.9 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	66.3 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	70.2 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	122 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	63.6 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	215 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	133 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	146 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	21.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	98.0 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	235 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	105 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	182 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	158 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	14.3 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	27.2 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	106 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	36.1 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	223 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	31.4 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	36.3 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	130 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	79.0 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	13.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	15.6 Titer (1/dilution)

Secondary

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)

GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT. FV non-immune participants were defined as participants with titer \< 10 (1/dilution) for all serotypes with parental dengue virus strains (sera tested by PRNT) and with titer \<10 (1/dilution) for YF virus (using sera with PRNT80 result).

Time frame: Pre-injection 1, 2, 3 and 28 days post-injection 1, 2 and 3

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	7.31 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	6.73 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	13.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	6.71 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	13.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	18.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	18.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	47.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	18.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	42.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	22.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	13.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	30.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	19.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	46.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	197 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	54.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	122 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	62.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	91.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	145 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	27.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	8.18 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	32.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	135 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	10.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	30.7 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	82.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	13.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	58.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	47.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	8.97 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	27.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	51.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	14.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	34.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	89.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	54.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	15.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	229 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	10.3 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	11.6 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	30.8 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	23.1 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	20.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	46.4 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	47.8 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	8.00 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	18.2 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	9.06 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	71.2 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	18.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	7.50 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	17.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	7.76 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	42.8 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	10.9 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	10.8 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	30.2 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	18.5 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue and Yellow Fever Vaccine: Group 3	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	5.00 Titer (1/dilution)

Secondary

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2

GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue PRNT.

Time frame: Pre-injection 1 and 2 and 28 days post-injection 1 and 2

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	5.38 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 1	10.3 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 2	11.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 2	18.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	5.19 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 1	30.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 2	38.4 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 2	64.1 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	5.32 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 1	32.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 2	26.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 2	47.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	5.78 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 1	121 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 2	60.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 2	104 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 2	111 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	5.13 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	5.28 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 1	8.75 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	5.11 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 2	11.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 1	31.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 2	14.9 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 2	89.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	5.22 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 2	34.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 1	24.2 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 1	126 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 2	40.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 2	62.0 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 2	66.9 Titer (1/dilution)

Secondary

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3

GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue plaque reduction neutralization test-50 (PRNT50). Groups 1 and 2 data was reported as pooled data. YF-non immune participants were defined as participants with YF baseline titer PRNT80 \< 10 (1/dilution).

Time frame: Pre-injection 1 and 28 days post-injection 1

Population: Analysis was performed on Full Analysis Set. Here, Overall number of participants analyzed = participants evaluable for this outcome measure and 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected, analyzed for Group 4.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: Pre-injection 1	5.19 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: 28 days Post-injection 1	8.71 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: Pre-injection 1	5.06 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: 28 days Post-injection 1	18.8 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: Pre-injection 1	5.21 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: 28 days Post-injection 1	28.5 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: Pre-injection 1	5.43 Titer (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: 28 days Post-injection 1	229 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: 28 days Post-injection 1	22.6 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: Pre-injection 1	5.00 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: Pre-injection 1	5.28 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: 28 days Post-injection 1	7.68 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: Pre-injection 1	5.26 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: Pre-injection 1	5.06 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: 28 days Post-injection 1	8.88 Titer (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: 28 days Post-injection 1	10.8 Titer (1/dilution)

Secondary

Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine

Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: \>100 mm.

Time frame: Within 7 days after any injection

Population: Analysis was performed on Safety Analysis set which included participants who received at least one injection of CYD dengue vaccine or YF vaccine. Here, Overall number of participants analyzed signifies participants evaluable for this outcome measure.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: CYD Dengue Vaccine	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: CYD Dengue Vaccine	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: CYD Dengue Vaccine	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: CYD Dengue Vaccine	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: CYD Dengue Vaccine	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: CYD Dengue Vaccine	44 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: CYD Dengue Vaccine	59 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: CYD Dengue Vaccine	10 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: CYD Dengue Vaccine	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: CYD Dengue Vaccine	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: CYD Dengue Vaccine	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: CYD Dengue Vaccine	3 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: Yellow Fever Vaccine	NA Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: Yellow Fever Vaccine	NA Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: Yellow Fever Vaccine	1 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: Yellow Fever Vaccine	5 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: Yellow Fever Vaccine	2 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: CYD Dengue Vaccine	0 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: Yellow Fever Vaccine	53 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: Yellow Fever Vaccine	0 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: CYD Dengue Vaccine	1 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: CYD Dengue Vaccine	51 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: CYD Dengue Vaccine	1 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: Yellow Fever Vaccine	0 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: CYD Dengue Vaccine	0 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: CYD Dengue Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: CYD Dengue Vaccine	NA Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: CYD Dengue Vaccine	NA Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: CYD Dengue Vaccine	NA Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: CYD Dengue Vaccine	NA Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Pain: Yellow Fever Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: Yellow Fever Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Pain: Yellow Fever Vaccine	10 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: Yellow Fever Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Erythema: Yellow Fever Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Grade 3 Swelling: Yellow Fever Vaccine	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Erythema: CYD Dengue Vaccine	NA Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Any Injection site Swelling: CYD Dengue Vaccine	NA Participants

Secondary

Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine

Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: \>= 39.0°C; Headache, Malaise, Myalgia, and Asthenia: significant; prevents daily activity.

Time frame: Within 14 days after any injection

Population: Analysis was performed on Safety Analysis Set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Any Grade	7 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Grade 3	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Any Grade	59 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Grade 3	4 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Any Grade	63 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Grade 3	10 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Any Grade	51 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Grade 3	6 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Any Grade	41 Participants
CYD Dengue Vaccine: Group 1	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Grade 3	6 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Any Grade	60 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Any Grade	36 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Grade 3	5 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Any Grade	53 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Grade 3	8 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Any Grade	47 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Grade 3	5 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Grade 3	3 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Any Grade	5 Participants
CYD Dengue Vaccine: Group 2	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Grade 3	1 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Grade 3	9 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Any Grade	54 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Grade 3	6 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Any Grade	4 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Grade 3	6 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Grade 3	10 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Any Grade	40 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Grade 3	0 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Any Grade	53 Participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Any Grade	64 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Any Grade	12 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Grade 3	2 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Malaise: Grade 3	3 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Grade 3	2 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Myalgia: Any Grade	8 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Grade 3	0 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Any Grade	11 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Headache: Grade 3	1 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Fever: Any Grade	1 Participants
Yellow Fever Vaccine: Group 4	Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine	Asthenia: Any Grade	9 Participants

Secondary

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)

Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). FV immune participants at baseline were defined as participants with titer \>= 10 (1/dilution) for at least 1 serotype with parental dengue virus strain (sera tested by PRNT) or with titer \>=10 (1/dilution) for YF virus (sera with PRNT80 result).

Time frame: Pre-injection 1, 2, 3 and 28 days post-injection 1, 2 and 3

Arm	Measure	Group	Value (NUMBER)
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	1.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	47.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	51.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	67.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	45.1 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	54.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	3.2 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	79.4 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	75.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	88.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	70.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	84.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	4.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	74.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	80.4 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	90.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	74.5 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	84.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	12.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	65.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	76.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	81.1 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	74.5 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	82.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	78.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	4.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	7.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	85.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	26.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	86.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	63.1 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	38.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	66.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	76.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	61.9 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	95.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	94.9 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	36.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	70.8 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	94.9 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	61.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	75.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	88.1 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	4.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	92.1 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	1.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	69.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	61.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	81.8 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	72.7 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	88.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	90.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	88.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	54.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	90.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	81.8 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	18.2 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	45.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	77.8 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	54.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	100.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	70.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	55.6 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	88.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	88.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	27.3 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	36.4 percentage of participants

Secondary

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)

Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). FV non-immune participants were defined as participants with titer \< 10 (1/dilution) for all serotypes with parental dengue virus strains (sera tested by PRNT) and with titer \<10 (1/dilution) for YF virus (using sera with PRNT80 result).

Time frame: Pre injection 1, 2, 3 and 28 days post injection 1, 2 and 3

Population: Analysis was performed on Full Analysis Set. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure and 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Arm	Measure	Group	Value (NUMBER)
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	18.5 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	17.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	47.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	19.1 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	50.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	48.1 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	46.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	83.3 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	55.3 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	83.3 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	50.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	41.2 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	68.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	63.8 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	85.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	70.4 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	66.0 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	87.5 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	80.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	95.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	82.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	68.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	22.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	72.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	73.1 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	32.1 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	61.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	79.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	41.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	79.2 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	85.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	28.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	60.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	79.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	51.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	60.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	83.3 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	75.5 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	40.7 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	75.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 1	33.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 2	33.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 2	68.9 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 3	57.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 1	46.1 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: 28 days Post-injection 3	83.3 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 3	77.6 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 1	0.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 1	21.4 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 2	41.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 2	26.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 3	84.3 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 2	52.2 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 1	0.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 1	19.4 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: Pre-injection 3	50.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 2	22.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: 28 days Post-injection 2	67.8 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 2	36.7 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: Pre-injection 3	39.3 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 3: 28 days Post-injection 3	73.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 1: 28 days Post-injection 3	59.5 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 2: Pre-injection 1	0.0 percentage of participants
CYD Dengue and Yellow Fever Vaccine: Group 3	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)	Dengue Virus Serotype 4: Pre-injection 1	0.0 percentage of participants

Secondary

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2

Time frame: Pre-injection 1 and 2 and 28 days post-injection 1 and 2

Arm	Measure	Group	Value (NUMBER)
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	1.7 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 1	34.2 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 2	35.5 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 2	58.4 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	0.9 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 1	65.0 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 2	61.3 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 2	86.1 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	2.6 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 1	63.2 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 2	61.7 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 2	80.2 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	6.8 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 1	67.8 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 2	71.7 Percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 2	84.2 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 2	80.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 1	2.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 1	4.2 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 1	24.6 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 1	0.8 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: Pre-injection 2	35.6 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 1	64.1 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 1: 28 days Post-injection 2	52.6 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: Pre-injection 2	67.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 1	2.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: Pre-injection 2	66.1 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 1	56.3 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 4: 28 days Post-injection 1	67.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: Pre-injection 2	68.6 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 3: 28 days Post-injection 2	84.5 Percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2	Dengue Virus Serotype 2: 28 days Post-injection 2	87.9 Percentage of participants

Secondary

Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3

Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution). Groups 1 and 2 data was reported as pooled data. YF-non immune participants were defined as participants with YF baseline titer dengue plaque reduction neutralization test-80 (PRNT80) \<10 (1/dilution).

Time frame: Pre-injection 1 and 28 days post-injection 1

Arm	Measure	Group	Value (NUMBER)
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: Pre-injection 1	1.7 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: 28 days Post-injection 1	23.3 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: Pre-injection 1	0.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: 28 days Post-injection 1	46.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: Pre-injection 1	2.6 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: 28 days Post-injection 1	57.9 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: Pre-injection 1	3.4 percentage of participants
CYD Dengue Vaccine: Group 1	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: 28 days Post-injection 1	74.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: 28 days Post-injection 1	48.6 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: Pre-injection 1	0.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: Pre-injection 1	2.8 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 1: 28 days Post-injection 1	20.4 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 4: Pre-injection 1	1.9 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: Pre-injection 1	0.9 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 3: 28 days Post-injection 1	25.0 percentage of participants
CYD Dengue Vaccine: Group 2	Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3	Dengue Virus Serotype 2: 28 days Post-injection 1	35.2 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2

Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3

Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine

Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)

Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2

Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3